Bacillary angiomatosis in an HIV seronegative patient on systemic steroid therapy

Schwartz, Robert A.; Gallardo, M. A.; Kapila, Rajendra; Gascón, Pere; Herscu, J.; Siegel, Israel; Lambert, W. Clark

doi:10.1046/j.1365-2133.1996.d01-1107.x

Cited by 31 publications

(33 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bacillary angiomatosis may resemble KS both clinically and histologically [80,81]. Histologically, the Grocott-methenamine silver stain and the Warthin-Starry stain at pH 3.2 show the bacterial etiologic agent to good advantage, although these bacteria may also be evident employing the hematoxylin-eosin, periodic acid-Schiff, and alcian blue stains.…”

Section: Differential Diagnosesmentioning

confidence: 96%

Kaposi's sarcoma: An update

Schwartz

2004

Journal of Surgical Oncology

126

114

View full text Add to dashboard Cite

While there have been many important advances in the study of Kaposi's sarcoma (KS), it remains both a challenge and an enigma in many ways. Kaposi's original description of "multiple idiopathic hemorrhagic sarcoma[s]" in patients who died within 2-3 years resembles KS in AIDS more than classic KS in elderly men of Italian, Jewish, or Mediterranean lineage, in whom the disease is usually benign. KS had been evident in about one-third of those with early AIDS, often as its presenting sign, a pattern markedly reduced in recent times since the introduction of highly active anti-retroviral therapy (HAART). The most important advance has been the convincing etiologic linkage of KS with human herpesvirus 8 (HHV-8), which is necessary but not sufficient. It has a low prevalence in the general population of the USA and UK, with an intermediate rate in Italy and Greece, and a high one in Uganda. KS risk may be significantly lower in AIDS patients with a history of anti-herpes therapy. Many aspects of HHV-8, including its transmission pattern and different genospecies, are being scrutinized. The diagnosis of KS may be difficult. One should be aware of KS clinical variants, including telangiectatic, eccymotic, and keloidal KS. One must consider a number of other disorders, including bacillary angiomatosis. HHV-8 DNA sequences in dermatofibromas and other tumors should probably not be viewed as representing a marker for KS. Therapeutic options vary for KS. Intralesional and low-dose outpatient intravenous vinblastine may be valuable, as immunosuppression with KS is not a good idea if it can be avoided. Anti-herpes virus therapy may have potential for wide use, especially in preventing the development of KS in at risk populations, such as HHV-8 seropositive individuals undergoing transplantation surgery.

show abstract

Section: Differential Diagnosesmentioning

confidence: 96%

Kaposi's sarcoma: An update

Schwartz

2004

Journal of Surgical Oncology

126

114

View full text Add to dashboard Cite

show abstract

“…223 BA may resemble KS both clinically and histologically (Fig 14). [232][233][234] Cutaneously, typical BA is a violaceous angiomatous tumor or a nodule resembling a pyogenic granuloma. Subcutaneous nodules, with or without ulceration, are sometimes seen.…”

Section: Differential Diagnosesmentioning

confidence: 99%

“…[224][225][226][227][228][229][230][231][232][233][234][235][236][237] Patch stage KS may resemble large junctional melanocytic nevi or a nevus flammeus. Pseudo-KS and BA merit special consideration.…”

Section: Differential Diagnosesmentioning

confidence: 99%

Kaposi sarcoma: A continuing conundrum

Schwartz

Micali

Nasca

et al. 2008

Journal of the American Academy of Dermatology

202

212

View full text Add to dashboard Cite

“…[2][3][4][5] The disease is common in immunocompromised patients, mainly patients with HIV infection. 2,6 Histologic study shows circumscribed lobular proliferations of the small blood vessels. 4 The etiologic agent of bacillary angiomatosis is Bartonella henselae or B quintana.…”

mentioning

confidence: 99%